

Title (en)

FGF21 COMBINED WITH CCR2/5 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS

Title (de)

FGF21 IN KOMBINATION MIT CCR2/5-ANTAGONISTEN ZUR BEHANDLUNG VON FIBROSE

Title (fr)

FGF21 COMBINÉ À DES ANTAGONISTES DE CCR2/5 POUR LE TRAITEMENT DE LA FIBROSE

Publication

EP 4192495 A1 20230614 (EN)

Application

EP 21773170 A 20210806

Priority

- US 202063063189 P 20200807
- US 202063065414 P 20200813
- US 202063065749 P 20200814
- US 202063065935 P 20200814
- US 202063067184 P 20200818
- US 2021045090 W 20210806

Abstract (en)

[origin: WO2022032187A1] The present application provides methods of treating a fibrosis and/or diabetes comprising administering a FGF-21 polypeptide in combination with a CCR2/5 dual antagonist. The method can also be used to treat NASH.

IPC 8 full level

A61K 38/18 (2006.01); **A61K 31/4178** (2006.01); **A61K 31/53** (2006.01); **A61K 47/60** (2017.01); **A61P 1/16** (2006.01)

CPC (source: EP)

A61K 31/517 (2013.01); **A61K 31/53** (2013.01); **A61K 38/1825** (2013.01); **A61K 47/60** (2017.08); **A61P 1/16** (2018.01)

C-Set (source: EP)

1. **A61K 31/53 + A61K 2300/00**
2. **A61K 31/517 + A61K 2300/00**

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2022032187 A1 20220210; EP 4192495 A1 20230614; JP 2023538533 A 20230908

DOCDB simple family (application)

US 2021045090 W 20210806; EP 21773170 A 20210806; JP 2023509393 A 20210806